Menu

News

25.09.2018

MaxiVAX starts Phase 2 study in Switzerland of innovative cancer vaccine in patients with Head & Neck cancer

·  Company winner of 2017 CTI Swiss Medtech Award

·  US FDA accepted IND in 2018

MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today the start of an open label Phase 2 study to evaluate its MVX-ONCO-1 product in 40-45 patients with Head & Neck cancer. The study is being conducted across different sites in Switzerland in collaboration with SAKK, the Swiss Group for Clinical Cancer Research. All enrolled patients will have a confirmed diagnosis of Head and Neck Squamous Carcinoma (HNSCC), stage III/IV in recurrent or metastatic stage and will have failed standard therapy. The primary endpoint is overall survival at 26 weeks.

PDF: English Français

17.07.2018

MaxiVAX appoints T. Scott Johnson, M.D., as new Chairman

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as Chairman, following his joining of the Board of Directors in December 2017. Dr Johnson takes over as Chairman from Dr Bernard Mach, co-founder of MaxiVAX, who remains on the Board. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.

PDF: English Français

MaxiVAX announces that US FDA accepts Investigational New Drug Application

Geneva, Switzerland, 17 July 2018 - MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct clinical trials in the US with its product MVX-ONCO-1.

Dimitrios Goundis, PhD, Chief Executive Officer, commented: “The FDA’s acceptance of our IND is a significant milestone for MaxiVAX. This decision validates the product attributes of MVX-ONCO-1, the promise of the preclinical and clinical data, and the quality of our production & control systems. Above all it is testament to the ingenuity and expertise of our team who are determined to make this significant potential cancer therapy available to patients as soon as possible.”

PDF: English Français

14.12.2017

MaxiVAX appoints Scott Johnson as Board Director

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as a Board Director. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.

PDF: English Français Deutsch

MaxiVAX appoints Antonio Perez as Chief Medical Officer

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Antonio Perez MD Ph.D., as its Chief Medical Officer. He joins the company after holding senior medical positions at Novartis, Biogen Idec, Basilea, Almirall and Esteve. He has also been a medical advisor to many companies across Europe and the US.

PDF: English Français Deutsch

13.06.2017

MaxiVAX wins 2017 CTI Swiss Medtech Award

The 2017 CTI Swiss Medtech Award, presented at the Swiss Medtech Day on 13 June, has gone to the biotech company MaxiVAX. MaxiVAX and the Geneva University Hospitals received the CHF 15,000 prize for developing a new vaccine designed to help the immune system in cancer patients fight their own tumor cells. The award was presented by Federal Councillor Johann N. Schneider-Ammann before around 600 guests in the Kursaal, Bern.

Press release in English, French, German, Italian

Download the poster.

 01.06.2017

MaxiVAX is 1 of 3 companies nominated to receive the CTI Swiss Medtech Award 2017. The winner announcement and Award ceremony will be held in Bern during the Swiss Medtech Day, on June 13th 2017.

10.10.2016

MaxiVAX is presenting the final data of the primary endpoint of its First-In-Man study at the ESMO 2016 congress in Copenhagen.

See the poster.

07.04.2016

MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial

Read the full press release.

03.02.2016

Press Release: MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer

Read the full press release.

20.11.2015

Poster Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from MVX-ONCO-1 first-in-man Phase 1 Trial. 

26.10.2015

MaxiVAX will participate in the Bio-Europe 2015 conference, Munich, Germany, Nov 2-4, 2015

21.9.2015

MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results" has been selected by the 18th ECCO - 40th ESMO European Cancer Congress Scientific Committee as a Poster in the poster session "Immunotherapy of Cancer" on 26 September 2015 from 16:45 to 18:45 in Hall C. The poster has also been selected for a new special session called Poster Spotlight from 17:15 to 18:15